Barreto Joaquim, Luchiari Beatriz, Wolf Vaneza L W, Bonilha Isabella, Bovi Ticiane G, Assato Barbara S, Breder Ikaro, Kimura-Medorima Sheila T, Munhoz Daniel B, Quinaglia Thiago, Coelho-Filho Otavio R, Carvalho Luiz Sergio F, Nadruz Wilson, Sposito Andrei C
Atherosclerosis and Vascular Biology Laboratory (Aterolab), Division of Cardiology, State University of Campinas (Unicamp), Sao Paulo 13083-894, Brazil.
Division of Cardiology, Department of Internal Medicine, Unicamp, Sao Paulo 13083-970, Brazil.
Diagnostics (Basel). 2022 Mar 26;12(4):814. doi: 10.3390/diagnostics12040814.
Stricter control of risk factors has been pursued as a compelling strategy to mitigate cardiovascular events (CVE) in type 2 diabetes (T2D) individuals. However, the achievement rate of the recommended goals has remained low in clinical practice. This study investigated the 2019 ESC guideline recommendation attainment among T2D individuals enrolled in a national cohort held in Brazil. Data from 1030 individuals (mean age: 58 years old; 54% male; mean T2D duration: 9.7 years) were analyzed. The control rates were 30.6% for SBP, 18.8% for LDL-C, and 41% for A1c, and only 3.2% of the study participants met all three targets. Statins and high-intensity lipid-lowering therapy prescription rates were 45% and 8.2%, respectively. Longer T2D duration and those at higher CV risk were less likely to be controlled. Longer diabetes duration and higher CV risk were inversely related to the chance of achieving the recommended targets. Treatment escalation using conventional therapies would be sufficient to gain optimal control in most of the study sample. In conclusion, a minimal proportion of T2D individuals comply with guidelines-oriented CV prevention targets. Given the significant burden of the disease, and the substantial effect size predicted for these therapies, bridging this gap between guidelines and clinical practice should be considered an urgent call to public health managers.
对风险因素进行更严格的控制已成为减轻2型糖尿病(T2D)患者心血管事件(CVE)的一项极具说服力的策略。然而,在临床实践中,推荐目标的达成率一直很低。本研究调查了巴西一个全国性队列中T2D患者对2019年欧洲心脏病学会(ESC)指南建议的达标情况。分析了1030名患者的数据(平均年龄:58岁;54%为男性;平均T2D病程:9.7年)。收缩压(SBP)、低密度脂蛋白胆固醇(LDL-C)和糖化血红蛋白(A1c)的控制率分别为30.6%、18.8%和41%,只有3.2%的研究参与者达到了所有三个目标。他汀类药物和高强度降脂治疗的处方率分别为45%和8.2%。T2D病程较长以及心血管风险较高的患者控制的可能性较小。糖尿病病程较长和心血管风险较高与达到推荐目标的机会呈负相关。在大多数研究样本中,使用传统疗法逐步升级治疗足以实现最佳控制。总之,只有极小比例的T2D患者符合以指南为导向的心血管预防目标。鉴于该疾病的巨大负担以及这些疗法预计的显著效应量,弥合指南与临床实践之间的差距应被视为对公共卫生管理者的紧急呼吁。